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CIC 1417, Paris, FranceAbstractWe studied a cohort of 110 823 patients treated with oral hypoglycaemic agents for type 2 diabetes in southeastern France from 1 January
2008 to 31 December 2011, to identify inﬂuenza vaccination coverage trends and the patient and physician correlates of inﬂuenza vaccine
(IFV) uptake. We used French national health insurance fund (NHIF) databases to identify these patients and collect data on their IFV
reimbursement claims (IFVC) and patient and physician characteristics. We used multilevel multivariate polytomous logistic regressions to
test the correlates of IFVC. Between 2008 and 2011 the annual IFVC rate varied from 33.7% to 32.3% in the 18–64 age group and from
69.5% to 61.1% in the 65 + age group, among whom we saw a clear trend towards reduced vaccination after 2008. In the younger
group, the probability of regular vaccination each year from 2008 to 2011 increased with diabetes severity and duration, comorbidities,
and the number of general practitioner and nurse visits; it was higher among patients seeing endocrinologists and lower among low-
income patients than in other patients. In the older group, there was no association with either diabetes severity or physician specialty.
These results suggest different patterns of correlates of inﬂuenza vaccination according to age. Endocrinologists might help to improve
IFV uptake in the younger group of patients with type 2 diabetes. Communication strategies regarding inﬂuenza vaccination should be
adapted to age, and collaboration between healthcare professionals should be reinforced to achieve vaccination objectives for these patients.
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E-mail: pierre.verger@inserm.frIntroductionWorldwide, seasonal inﬂuenza causes 3–5 million serious ill-
nesses annually and 250 000–500 000 deaths, depending on theMicrobiol Infect 2015; 21: 930.e1–930.e9
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.017virulence of the virus and the duration of the epidemic [1]. The
World Health Assembly and the guidelines of most countries,
including France [2–4], recommend inﬂuenza vaccination every
year for groups at high risk of inﬂuenza-related complications
(persons 65 years of age or older or with speciﬁc chronic
diseases including diabetes). Although the target coverage rate
in Europe, including France, is 75% in all at-risk groups [5,6]
(80% in Canada [7], and in the USA [8], 90% among all per-
sons aged 65+ years and 60% among persons aged 18–64 years
who have risk factors), actual coverage for high-risk groups
remains below national targets in most countries [9]. It isious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Verger et al. Inﬂuenza vaccination in patients with diabetes 930.e2therefore essential to improve our understanding of the pre-
dictors of inﬂuenza vaccine (IFV) uptake in these groups,
especially patients with chronic diseases such as diabetes,
among whom these predictors have been studied somewhat
less than among older people.
Studies of adults with diabetes show that increasing age [9],
previous inﬂuenza vaccination [10], other comorbidities [11]
and having a regular health provider [12] are important posi-
tive predictors of IFV uptake and that low income and/or
residing in a deprived area are negative predictors [13]. The
few studies that have considered the characteristics of the
diabetes itself show that its severity [14] and duration [15] are
positively associated with IFV uptake. Although inﬂuenza
vaccination must be repeated annually, we are not aware of any
studies that have examined factors associated with it for several
consecutive years. Because physician advice is one of the most
important inﬂuences on the decision about this vaccination
[16,17], their characteristics may also help to predict it. Few
studies have considered both patients’ and physicians’
characteristics.
In view of the marked decrease of IFV uptake in the general
French population since the 2009 A/H1N1 pandemic in
France [18] and of the dramatic rise in unfavourable attitudes
towards vaccination in France during this pandemic [19], we
set up a cohort of patients treated with oral hypoglycaemic
agents (OHAs) for type 2 diabetes—referred to hereafter as
patients with diabetes— in southeastern France. We followed
up this cohort from 1 January 2008 through 31 December
2011. Our aims were: to estimate inﬂuenza vaccination
coverage from 2008 to 2011; and to study patient (socio-
demographic, diabetes severity, comorbidities and care-
seeking behaviour) and physician (demographic, specialty
and practice of alternative medicine) characteristics corre-
lated with IFV uptake.MethodsDatabase
We used the databases of the French national health insurance
fund (NHIF) in southeastern France to identify the patients with
diabetes and collect data on IFV purchases and patient and
physician characteristics. This fund covers all but 13% of the
population (i.e. it does not cover students, farmers and farm
workers, and self-employed workers). Its databases record all
drugs prescribed by a physician and dispensed in community
pharmacies. For each prescription, the databases contain the
prescription and purchase dates and prescriber and patient
identiﬁers. The French national data protection authority
(CNIL) approved this study.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InPatient inclusion and exclusion criteria
We included patients aged 18 years or more in 2008 who
purchased an OHA (A10B under the Anatomical, Therapeutic,
Chemical Classiﬁcation System) at least once in 2008 and at
least twice during the following 12-month period. We used this
previously published method [20] because the NHIF databases
do not routinely contain diagnosis information. The diabetes
was classiﬁed as incident if the patient had not been reimbursed
for an OHA or insulin in 2007 and prevalent otherwise. The
inclusion date was deﬁned as the date of the ﬁrst reimburse-
ment for OHA for incident cases and 1 January 2008, for
prevalent cases.
Patients whose type 1 diabetes was ofﬁcially recognized as a
chronic disease were excluded, but they accounted for only
4.3% of the initial subjects. Chronic disease status is attributed
to people with speciﬁc and expensive chronic diseases deﬁned
by NHIF and makes them eligible for 100% reimbursement for
treatment. In addition, every 1 January for the years 2009–11,
we censored the patients who had died or left the southeastern
France NHIF during the previous year.
Inﬂuenza vaccination
We used inﬂuenza vaccine reimbursement claims (IFVCs)
recorded in the NHIF database (Anatomical, Therapeutic,
Chemical Classiﬁcation System codes J07BB01, J07BB02) be-
tween 30 September and 31 December of each year as a proxy
to estimate IFV uptake for each vaccination campaign. During
the study period, the seasonal inﬂuenza vaccination campaigns
in France did not start earlier than 30 September, lasted for 3
months, and extended for a tiny percentage of the population
( 0.8%) into January of the following year. As data for January
2012 were not available at the time of the study, we calculated
the IFVC at year n over the study period and excluded data for
January at year n + 1 from annual rate numerators. We con-
structed an individual IFVC score (range: 0–4) equal to the
individual’s total number of IFV claims in 2008–11.
Patients’ characteristics
From the NHIF database, we collected the following patient
data: age on 1 January 2008; gender; CMUC (Complementary
Universal Health Insurance, a programme that exempts in-
dividuals who have annual incomes below V 9000 from any
out-of-pocket costs and is therefore a proxy for very low in-
come [21]); and number of consultations or visits with general
practitioners (GPs) and nurses during the follow-up period.
Based on chronic disease status and International Classiﬁcation
of Diseases, 10th edition codes, we constructed a proxy vari-
able for comorbidity in four classes: no chronic disease status,
chronic disease status for type 2 diabetes, or for other diseases
at high risk of complicating inﬂuenza (Appendix 1), or ﬁnally forfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
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constructed a treatment intensity variable in three classes as a
proxy for diabetes severity, applying the graded strategy of
diabetes care according to its severity recommended in France
[22]: one single OHA, two or more OHAs, or at least one
insulin claim during the follow-up period.
Physicians’ characteristics
Each patient was linked to the physician who wrote the most
OHA prescriptions for him or her during the 12 months after
inclusion, on the assumption that this physician was responsible
for the patient’s care. Physician data included the following
variables: age; gender; specialty (GP, endocrinologist, other) and
practice of alternative medicine (for example, acupuncture or
homeopathy). Data about GPs’ clienteles included the per-
centage of patients with chronic disease status.
Statistical analyses
We conducted descriptive and regression analyses separately in
the group aged 18–64 years and the group aged 65 years or
older (65+ age group).
Descriptive analyses
We estimated IFV uptake each year as the ratio of patients with
diabetes and an IFVC between 30 September and 31 December
to the number of patients with diabetes identiﬁed in the data-
base on 1 January of the same year.
We used chi-squared tests to compare IFVC rates across age
classes and McNemar tests to assess changes over the study
period, while taking paired data into account.
Regression models
The dependent variable was the number of IFVCs in the
2008–11 period in three categories: 0, 1–2 or 3–4. We ran
univariate polytomous logistic regressions and then multilevel
multivariate polytomous logistic regressions to test the patient
and physician characteristics correlated with the dependent
variable. Multilevel models allowed us to take the hierarchical
structure of the data into account (level 1, the patients,
embedded in level 2, the physicians) and to estimate inter-
individual and inter-physician variability. We ﬁrst tested a null
model (with no variables) to evaluate the signiﬁcance of inter-
physician variability and assess whether or not the multilevel
approach was justiﬁed. Next, we tested a model that included
only patient characteristics, and ﬁnally, a full model with both
patient and physician characteristics. The following adjustment
variables were forced into the multilevel models: patient age,
gender, and place of residence, at the individual level; physician
age, gender, and clientele characteristics (percentage of practice
patients with chronic disease status), at the physician level. AllClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectof the other explanatory variables were also included in the
models, for all were signiﬁcantly associated at the univariate
step with at least one of the two categories of the dependent
variable (1–2 or 3–4 claims versus 0), with p <0.01. Because
retired people are not eligible for CMUC, we could not
introduce this variable in the multilevel model for people aged
65 years or more. To approximate relative risks, odds ratios
were corrected with the Zhang and Yu method [23]. We
performed the analyses with SAS 9.2 software.ResultsWe identiﬁed 137 447 adults with type 2 diabetes treated with
OHAs in January 2008 in southeastern France and were able to
link 133 131 (96.9%) to a physician (n = 6316; mean number of
patients per physician: 17.5). Among these patients, 110 823
(83.2%) could be followed for the entire study period and were
included in the analysis: 55.4% belonged to the 65+ age group,
53.9% were men, 48.7% were treated with two OHAs and
18.3% with insulin (Table 1). Most of these patient character-
istics were similar to those of patients at inclusion before the
linkage to a physician, but the former had a chronic disease
status more frequently than the latter. Most physicians were
men (75.2%) and GPs (83.0%); 2.0% were endocrinologists; and
4.5% practiced an alternative form of medicine.
Claims for inﬂuenza vaccination
Every year, IFVC rates were twice as high in the 65+ age group
as in those aged 18–64 years (Table 2). In both groups, IFVC
rates were signiﬁcantly lower in 2011 than in 2008 (McNemar
tests, p <0.001); the difference was greater in the 65+ age
group. In the 18–64 age group, 20% of the patients had 1–2
IFVCs recorded during the study period 2008–11 and 32.1%
had 3–4 IFVCs recorded. In the 65+ age group, the corre-
sponding ﬁgures were 14.5% and 65.1%.
Factors associated with the IFVC score during the
2008–11 period in the 18–64 age group
The empty multilevel regression model for the 18–64 age
group showed signiﬁcant inter-physician variability, which
justiﬁed the use of a hierarchical approach (p <0.001). The
results of the multilevel model regarding patient characteristics
were similar to those of univariate models, although some
relative risks were signiﬁcantly lower in the multilevel model
(Table 3): the IFVC score was signiﬁcantly higher in men, pa-
tients with prevalent (versus incident) diabetes and those with
chronic disease status for diabetes or other chronic diseases,
and it rose signiﬁcantly with age, diabetes severity and number
of visits with GPs and with nurses; it was signiﬁcantly lower inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
TABLE 1. Characteristics of the cohort patients at inclusion
and at follow up (patients treated with oral hypoglycaemic
agents, southeastern France)
Initial cohort
Cohort of
patients with
a regular
physician
Cohort of
patients with
a regular
physician and
present from
inclusion to the
31/12/2011
(n[ 137 447) (n[ 133 131) (n [ 110 823)a
% % %
Sex
Women 46.4 46.6 46.2
Men 53.6 53.4 53.9
Age, years
18–49 9.1 9.0 8.8
50–59 20.2 20.2 20.6
60–64 14.6 14.6 15.3
65–69 14.2 14.2 15.1
70–79 28.7 28.8 29.3
80 13.1 13.2 11
Diabetes severity
A single OHAb 35.4 35.2 33.0
Combination of at least
two OHAsc
46.2 46.4 48.7
OHA and insulind 18.4 18.4 18.3
Type of diabetes
Prevalent 86.0 86.0 89.9
Incident 14.0 14.0 11.1
Mean annual consultations with GPs
<5 24.0 23.3 23.7
5–12 51.7 52.0 53.4
>12 24.3 24.7 22.9
Mean annual visits with nurses
0 33.1 33.1 29.1
1–7 42.7 42.5 46.2
>7 24.2 24.4 24.6
Recognized chronic disease status
No 23.2 23.1 16.6
Yes, for diabetes 65.2 65.3 71.3
Yes, for other at-risk
conditions (besides
diabetes—only or
associated)
2.3 2.3 2.3
Yes for other conditions
not at-risk
9.4 9.4 9.8
CMUC (in 18–64 year-olds)
Yes 11.9 12.0 11.4
No 88.1 88.0 88.6
aAlthough sometimes quite small, all differences between percentages (column 3
versus columns 1) are statistically signiﬁcant (chi-squared tests, p <0.05) because of
the large sample size.
bOral hypoglycaemic agent: a single OHA per prescription.
cAt least one prescription with two different OHAs.
dInsulin during the follow-up period.
CMI Verger et al. Inﬂuenza vaccination in patients with diabetes 930.e4patients on very low income (with CMUC). Regarding physician
factors, the IFVC scores were signiﬁcantly lower for patients
who are mainly treated for their diabetes by private endocri-
nologists or other specialists or by physicians practicingTABLE 2. Rates of inﬂuenza vaccination claims according to year an
agents, southeastern France)
2008 campaign 2009 campaign
All aged 18 years or older 53.6 58.5
Population aged 18–64 yearsb 33.7 39.0
Population aged 65 years or olderb 69.5 72.3
aMean over the 4 campaigns (2008-2001).
bAge on 1 January of each year.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inacupuncture/homeopathy in the univariate analyses. Results in
the multilevel model were somewhat different: the IFVC score
was higher for patients treated by private endocrinologists and
no longer differed (except in the ‘1–2’ score category) for
those treated by physicians practicing acupuncture/homeopathy
(Table 3).
Factors associated with the IFVC score during 2008–11
in the 65+ age group
Again, the empty multilevel model showed signiﬁcant inter-
physician variability (p <0.001). The pattern of the relations
between patient factors and the IFVC score were somewhat
different than for the 18–64 group: for most explanatory
variables, the corresponding relative risks were lower for the
older group in both the univariate and multilevel steps,
especially for the comorbidity variable, and the IFVC score
was not associated with diabetes severity (Table 4). Looking
at the physician factors, we found a clearly lower IFVC score
in both the univariate and multilevel models for patients
treated by physicians who practiced acupuncture/
homeopathy.DiscussionThis study is the ﬁrst in France to examine inﬂuenza vaccina-
tion in patients treated for type 2 diabetes, a condition targeted
by recommendations regarding inﬂuenza vaccination. On
average, nearly half of these patients in southeastern France
had an IFVC each year over the 2008–11 period; a clearly
decreasing trend, beginning in 2009, was visible. The annual
IFVC rate was about twice as high in the 65+ age group as
among the younger patients. Among the latter, the probability
of being regularly vaccinated (3–4 times) during the study
period increased with diabetes severity and duration, the
presence of comorbidities (highest relative risk), and the
number of consultations/visits with GPs and with nurses and
decreased in low-income patients. In this group, IFVC rates
were higher among patients mainly treated for their diabetes by
endocrinologists. In the 65+ age group, the pattern of corre-
lates was somewhat different, with lower relative risks ford age (%; n[ 110 823 patients treated with oral hypoglycaemic
2010 campaign 2011 campaign 2008–2011 campaignsa
51.6 51.1 53.7
32.5 32.3 34.4
63.4 61.1 66.6
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
TABLE 3. Patients’ and physicians’ characteristics associated with the number of inﬂuenza vaccination claims (IFVC) over the 2008-
2011 period in patients treated with oral hypoglycaemic agents (OHA): 18–64 age group, multilevel polytomous logistic regression
(n [ 49 419, southeastern France)a
%
Vaccinated 1–2 times Vaccinated 3–4 times
(n [ 9 871; 20.0%) (n [ 15 884; 32.1%)
RR (95% CI) b RRa (95% CI) c RR (95% CI) RRa (95% CI)
INDIVIDUAL LEVEL
Sex
Women (ref.) 43 1 1 1 1
Men 57 1.02 (0.99–1.06) 1.04 (1.00–1.08) 1.10 (1.08–1.13) 1.12 (1.09–1.15)
Age, years
18–49 (ref.) 20 1 1 1 1.
50–59 46 1.22 (1.16–1.28) 1.21 (1.15–1.26) 1.55 (1.48–1.62) 1.48 (1.42–1.55)
60–64 34 1.63 (1.55–1.71) 1.69 (1.61–1.76) 2.28 (2.19–2.38) 2.27 (2.20–2.34)
Diabetes severity
A single OHAd (ref.) 30 1 1 1 1
Combination of at least two OHAse 53 1.28 (1.23–1.33) 1.07 (1.02–1.12) 1.36 (1.32–1.40) 1.08 (1.05–1.12)
OHA and insulinf 17 1.51 (1.44–1.59) 1.20 (1.13–1.27) 1.62 (1.56–1.68) 1.22 (1.17–1.28)
Type of diabetes
Prevalent (ref.) 85 1 1 1 1
Incident 15 0.74 (0.70–0.78) 0.87 (0.83–0.92) 0.52 (0.49–0.54) 0.66 (0.63–0.69)
Mean annual consultations with GPs
<5 (ref.) 28 1 1 1 1
5–12 52 1.46 (1.40–1.52) 1.35 (1.29–1.41) 1.63 (1.58–1.69) 1.57 (1.52–1.62)
>12 20 1.82 (1.74–1.91) 1.69 (1.61–1.78) 1.94 (1.87–2.02) 1.98 (1.92–2.05)
Mean annual visits with nurses
0 (ref.) 38 1 1 1 1
1–7 47 1.31 (1.26–1.36) 1.23 (1.18–1.27) 1.65 (1.60–1.70) 1.52 (1.48–1.57)
>7 15 1.52 (1.45–1.59) 1.24 (1.17–1.31) 1.75 (1.68–1.81) 1.39 (1.33–1.45)
Recognized chronic disease status
No (ref.) 18 1 1 1 1
Yes, for diabetes 73 2.32 (2.20–2.46) 2.16 (2.06–2.26) 3.70 (3.48–3.92) 3.35 (3.22–3.49)
Yes, for other at-risk conditions 2 2.48 (2.18–2.81) 2.27 (1.98–2.57) 4.37 (4.01–4.76) 3.99 (3.67–4.31)
Yes, for other conditions; not at risk 8 1.37 (1.25–1.49) 1.16 (1.06–1.27) 1.63 (1.49–1.77) 1.24 (1.13–1.36)
CMUC
No (ref.) 89 1 1 1 1
Yes 11 1.03 (0.98–1.08) 0.95 (0.90–1.01) 0.80 (0.76–0.84) 0.80 (0.76–0.84)
PHYSICIAN LEVEL
Sex
Women (ref.) 22 1 1 1 1
Men 78 1.00 (0.96–1.04) 0.93 (0.89–0.98) 1.00 (0.97–1.03) 0.94 (0.91–0.98)
Age, years
<45 (ref.) 13 1 1 1 1
45–49 15 1.03 (0.96–1.09) 1.04 (0.97–1.11) 1.01 (0.96–1.05) 1.02 (0.97–1.07)
50–54 21 1.00 (0.95–1.06) 1.03 (0.97–1.10) 1.02 (0.98–1.06) 1.03 (0.98–1.08)
55–59 26 0.97 (0.92–1.03) 1.00 (0.94–1.07) 1.01 (0.97–1.05) 1.03 (0.98–1.08)
>60 26 0.98 (0.92–1.04) 1.01 (0.94–1.07) 0.99 (0.95–1.03) 1.00 (0.96–1.05)
Specialist
General practitioner (ref.) 90 1 1 1 1
Endocrinologist 7 0.77 (0.71–0.83) 0.90 (0.82–0.98) 0.94 (0.90–0.99) 1.11 (1.05–1.17)
Other 3 0.71 (0.63–0.79) 0.95 (0.85–1.06) 0.77 (0.71–0.83) 1.03 (0.95–1.12)
Particular type of practice
None (ref.) 98 1 1 1 1
Acupuncture/homeopathy 1 0.77 (0.63–0.93) 0.79 (0.65–0.96) 0.85 (0.74–0.97) 0.89 (0.77–1.02)
Other particular type of practice 1 0.95 (0.81–1.10) 1.00 (0.85–1.16) 0.94 (0.84–1.05) 0.97 (0.85–1.09)
aFor all of the relative risks presented, the reference category is “no inﬂuenza vaccination from 2008 to 2011” (n = 23 664 cohort members; 47.9%).
bCrude relative risk and 95% CI.
cAdjusted relative risk and 95% CI (polytomous multilevel logistic regression).
dA single OHA per prescription.
eAt least one prescription with two different OHAs.
fInsulin during the follow-up period.
930.e5 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMImost of the explanatory variables than in the 18–64 age group
and no association with diabetes severity or with treatment by
an endocrinologist.
Despite speciﬁc recommendations for patients with diabetes
[3], the annual IFVC rates in the 18–64 age group (overall mean
34.4%) were strikingly lower than the objective of 75% IFV
uptake in high-risk groups in France and Europe [3,5]. Nor did
the coverage rate in older diabetic patients come close to
achieving this objective, although their IFVC rates were higher.
These results are consistent with previous publications showingClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthat IFV coverage objectives are not achieved in most countries,
especially among the youngest patients, at risk because of
chronic conditions [9,24,25]. A recent meta-analysis reported
that IFV is effective in subjects younger than 65 but failed to ﬁnd
evidence that it effectively protects adults aged 65 years or
older [26] and so fuelled a scientiﬁc debate about IFV effec-
tiveness. This debate has been reﬂected in some limited public
news media specializing in the ﬁeld of health, in the medical
press, and on internet sites. It may also reduce physicians’
willingness to recommend the vaccine to hesitant persons, e.g.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
TABLE 4. Patients’ and physicians’ characteristics associated with the number of inﬂuenza vaccination claims (IFVC) over the
2008–11 period in patients treated with oral hypoglycaemic agents (OHA): 65+ age group, multilevel polytomous logistic
regression (n [ 61 404, southeastern France)a
%
Vaccinated 1–2 times Vaccinated 3–4 times
(n [ 8889; 14.5%) (n [ 39 987; 65.1%)
RR 95% CIb RRa 95% CIc RR 95% CI RRa 95% CI
INDIVIDUAL LEVEL
Sex
Women (ref.) 49 1 1 1 1
Men 51 1.06 (1.03–1.10) 1.14 (1.11–1.18) 1.04 (1.03–1.05) 1.08 (1.07–1.09)
Age, years
65–69 (ref.) 27 1 1 1 1
70–79 53 1.00 (0.97–1.04) 0.97 (0.93–1.01) 1.08 (1.07–1.10) 1.07 (1.05–1.08)
80 20 1.22 (1.17–1.28) 1.14 (1.09–1.20) 1.16 (1.14–1.17) 1.13 (1.11–1.14)
Diabetes severity
A single OHAd (ref.) 36 1 1 1 1
Combination of at least two OHAse 45 1.00 (0.96–1.04) 1.01 (0.97–1.05) 0.99 (0.98–1.00) 0.98 (0.97–1.00)
OHA and insulinf 19 1.29 (1.24–1.34) 1.19 (1.14–1.24) 1.05 (1.04–1.07) 1.01 (0.99–1.03)
Type of diabetes
Prevalent (ref.) 92 1 1 1 1
Incident 8 0.96 (0.91–1.02) 1.01 (0.95–1.07) 0.91 (0.89–0.93) 0.94 (0.92–0.96)
Mean annual consultations with GPs
<5 (ref.) 20 1 1 1 1
5–12 55 1.28 (1.22–1.33) 1.23 (1.18–1.28) 1.26 (1.24–1.28) 1.24 (1.23–1.26)
>12 25 1.64 (1.56–1.71) 1.51 (1.44–1.57) 1.37 (1.34–1.39) 1.36 (1.34–1.38)
Mean annual visits with nurses
0 (ref.) 22 1 1 1 1
1–7 46 1.23 (1.18–1.28) 1.22 (1.17–1.27) 1.26 (1.24–1.28) 1.24 (1.22–1.25)
>7 33 1.46 (1.40–1.52) 1.27 (1.21–1.33) 1.26 (1.24–1.28) 1.16 (1.14–1.18)
Recognized chronic disease status
No (ref.) 16 1 1 1 1
Yes for diabetes 70 0.96 (0.92–1.00) 0.89 (0.86–0.94) 1.10 (1.08–1.12) 1.06 (1.05–1.08)
Yes for other at-risk conditions 3 1.12 (1.02–1.24) 1.01 (0.90–1.12) 1.15 (1.12–1.18) 1.09 (1.06–1.13)
Yes, for other conditions; not at risk 12 1.00 (0.96–1.05) 0.91 (0.86–0.97) 1.11 (1.09–1.13) 1.06 (1.03–1.08)
PHYSICIAN LEVEL
Sex
Women (ref.) 19 1 1 1 1
Men 81 1.05 (1.01–1.09) 0.99 (0.97–1.00) 1.00 (0.99–1.02) 0.99 (0.97–1.00)
Age, years
<45 (ref.) 11 1. 1 1 1
45–49 14 1.01 (0.95–1.08) 1.00 (0.98–1.02) 1.00 (0.98–1.02) 1.00 (0.98–1.02)
50–54 21 0.98 (0.92–1.04) 0.99 (0.97–1.01) 0.99 (0.98–1.01) 0.99 (0.97–1.01)
55–59 26 0.97 (0.92–1.03) 0.99 (0.97–1.01) 0.99 (0.97–1.01) 0.99 (0.97–1.01)
>59 27 0.97 (0.91–1.02) 0.97 (0.95–0.99) 0.97 (0.96–0.99) 0.97 (0.95–0.99)
Specialist
General practitioner (ref.) 93 1 1 1 1
Endocrinologist 4 0.88 (0.81–0.96) 0.97 (0.88–1.06) 0.99 (0.96–1.01) 1.03 (1.00–1.06)
Other 3 0.92 (0.83–1.01) 1.01 (0.91–1.11) 0.97 (0.94–1.00) 1.02 (0.99–1.05)
Particular type of practice
None (ref.) 98 1 1 1 1
Acupuncture/homeopathy 1 0.68 (0.57–0.81) 0.71 (0.59–0.85) 0.80 (0.75–0.86) 0.79 (0.73–0.85)
Other particular type of practice 1 1.03 (0.90–1.18) 1.03 (0.89–1.18) 1.01 (0.97–1.05) 1.01 (0.96–1.06)
aFor all of the relative risks presented, the reference category is “no inﬂuenza vaccination from 2008 to 2011” (n = 12 528 cohort members (20.4%)).
bCrude relative risk and 95% CI.
cAdjusted relative risk (adjusted corrected odds ratio) and 95% CI (polytomous multilevel logistic regression).
dA single OHA per prescription.
eAt least one prescription with two different OHAs.
fInsulin during the follow-up period.
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despite inﬂuenza vaccination.
Direct comparisons of our results with those of other
studies are difﬁcult because of methodological differences:
most of them were based on patient self-reports; calendar
years and age classes differed; and results have rarely been
presented according to both age category and presence/
absence of chronic diseases. European countries vary consid-
erably with regard to IFV coverage among high-risk groups in
adults with diabetes: the mean level is 54%, and the range is
22–79% [9].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InThe decrease in IFVC between 2009 and 2011 among pa-
tients with diabetes in France is consistent with previous pub-
lications at the national level [10,18,25]. As previously
observed, this decrease was especially marked in older people,
perhaps because coverage was highest for them. This decrease
might well reﬂect the effects of the pandemic vaccination
campaign in France on IFV behaviour [10,19]: the controversies
in 2009–10 and in particular the suspicion of conﬂicts of in-
terest between pharmaceutical companies and experts might
have created doubts about the safety of IFV in the French
population as well as among GPs and specialists and therebyfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
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period 2012–14 have stabilized among the 18–65 group with
at-risk conditions, but the decrease among the 65+ group ap-
pears to be ongoing [18].
Age was signiﬁcantly positively associated with IFVC in both
age groups (Tables 3 and 4) as previously observed [9,15].
Vaccine coverage higher in men than in women has previously
been observed for inﬂuenza vaccination among patients with
diabetes or other chronic conditions [28] as well as for
pandemic H1N1 vaccination among people with chronic con-
ditions [29]. At least two hypotheses, separately or together,
might explain this difference: men with a chronic condition
might be more concerned than women about possible com-
plications of their condition, or women might be more con-
cerned by potential adverse effects of the vaccine [30]. Patient
health status (diabetes severity, duration and comorbidities)
was strongly independently associated with IFVC in the 18–64
age group. This too is consistent with previous results among
patients with diabetes [14,15,28]. Severe morbidity may in-
crease perceived susceptibility to inﬂuenza and/or its severity,
factors associated with IFV uptake [7]. However, in the older
group, these associations between IFVC rates and patient health
were less marked (comorbidity) or absent (diabetes severity).
Our results suggest that healthcare use plays an important role
in inﬂuenza vaccination of patients with diabetes in both groups.
We used proxy variables (number of consultations/visits with
GPs/nurses) to measure this: these variables may reﬂect patients’
health needs, in terms of their health status and comorbid-
ities— factors we adjusted for in our models—as well as the in-
tensity and regularity of their care. TheNHIF sends at-risk patients
a voucher that enables them to obtain the IFV free of charge at
their community pharmacies. Since 2008, patients can see a nurse
directly for the shot with this voucher, without a prescription
from the physician, except for the ﬁrst shot. However, GPs play a
key role in explaining the need for vaccination, reminding their
patients about it and inﬂuencing their decision [17].
Our results also suggest the persistence of barriers to
inﬂuenza vaccination in patients with low income (Table 3),
measured in this study by the CMUC variable, a strong and
reliable indicator of deprivation [21]. Because inﬂuenza vacci-
nation is free-of-charge for at-risk groups in France, and the
CMUC welfare programme exempts low-income patients from
any out-of-pocket medical costs, our results suggest that atti-
tudinal barriers in this population play an important role [31].
Financial barriers nonetheless persist for some patients in the
18–64 age group with incomes just above the threshold of
eligibility for the CMUC programme and no complementary
insurance (IFV price: V 7). In particular, patients with diabetes
who do not have chronic disease status (i.e. 18% of the patients
treated for type 2 diabetes in the 18–64 age group in our study,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectTable 3) do not receive the free voucher for IFV and are less
likely to be vaccinated than patients who have chronic disease
status for diabetes (Table 3).
The results of the multilevel models among patients with
diabetes in the 18–64 age group suggest that treatment by a
private-practice endocrinologist could improve IFV uptake,
unless the observed link was related to unobserved con-
founding factors. Endocrinologists usually treat patients whose
diabetes is more severe or who have more complications or
comorbidities than those treated by GPs [32]. Adjustment for
patient health status may therefore explain the differences be-
tween the univariate and multilevel models (Table 3). Outpa-
tient visits to specialists are an under-recognized opportunity
for vaccination recommendations. A study of attitudes and
behaviours of specialists in the USA showed that most spe-
cialists recommend inﬂuenza vaccination to their high-risk pa-
tients aged 18–64 years [33].
Strengths and limitations of the study
Our design allowed us to follow up a large cohort of adults with
diabetes for several years and to analyse factors associated with
IFVC while considering characteristics of both patients and
physicians (from the NHIF database). It therefore represents an
important methodological improvement upon previous publi-
cations. Our results cannot be extrapolated to population cat-
egories covered by health insurance systems other than the
NHIF (e.g. students, farmers and other self-employed workers).
Nonetheless, the NHIF covers 87% of the population in south-
eastern France. Because the trends we observed over 2008–11
for southeastern France paralleled those at the national level
[34], our results can probably be extrapolated to the entire
country.We did not include patients with type 2 diabetes treated
with lifestyle and dietary measures alone; but these patients
represent a small minority of patients with diabetes in France
(about 10%) [35].We used IFVC as a proxy for IFV uptake.While
some purchased vaccines might not be used because people
might forget to have the shot or change their mind, the impact of
this on coverage estimations seems marginal [36]. Subjects’ self-
reports have been shown to overestimate inﬂuenza vaccination
coverage [37]. The lack of clinical data on the severity of diabetes
in the reimbursement databases of the French NHIF is a limita-
tion of this study. However, NHIF data enabled us to construct
several variables to serve as proxies for disease severity (in-
tensity of treatment, comorbidities, etc.). Finally, the study design
does not allow us to interpret the results in terms of causality.
To the best of our knowledge, this is the ﬁrst study in France
documenting inﬂuenza vaccination coverage and its correlates
in such a large cohort of adults with type 2 diabetes. The low
vaccination coverage rates observed in 2008–11, particularly in
the 18–64 age group, are a cause for concern, especially asious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 930.e1–930.e9
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These rates therefore raise questions about the current IFV
strategy in France. Our results suggest that the pattern of these
correlates changes as patients get older, probably because of a
change in perceived susceptibility to inﬂuenza (both infection
and severity). Although this ﬁnding should be conﬁrmed, it
suggests that communication strategies should be adapted to
age and to the perceived IFV beneﬁts. Our results also suggest
the importance of the role of endocrinologists— in the 18–64
age group—as well as nurses in addition to primary-care
physicians and indicate the potential for collaborative strate-
gies involving different healthcare professionals to achieve na-
tional inﬂuenza vaccination objectives for these patients.
To arrest and even reverse the decrease of inﬂuenza vacci-
nation rates observed since 2009, French Health authorities
have been relying on interventions combining spot TV cam-
paigns, dissemination of various booklets, and documents both
for the public and physicians that provide them with clear ex-
planations of the beneﬁts and potential risks of inﬂuenza
vaccination. Additionally, the NHIF launched in 2012 a payment
for performance system for GPs (not endocrinologists in pri-
vate practice); it includes payments if their patients’ inﬂuenza
vaccination rates meet speciﬁed levels. Despite these measures,
these rates continue to erode in the 65+ age group and have
not improved in younger patients with chronic conditions.
Furthering our knowledge about the barriers to inﬂuenza vac-
cine uptake and its drivers remains necessary, especially among
patients with chronic conditions. Further efforts are also
necessary to assess the effectiveness of IFV in these patients.AcknowledgementsThis study was implemented as part of a contract with the
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